Papers/PMID:41008575
Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial.
Biomolecules2025The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
Zn(2+) — no detected effect on Mini-Mental State Examination total score
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The mean differences between treatment and placebo groups were not statistically significant for any outcome (A: CC2, p = 1; B: CDR-Sob, p = 1; C: MMSE, p = 1).”
Quoted verbatim from Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial.. - Study
- RCT
- Duration
- 6 months
- Dose
- elemental zinc as zinc sulfate tablets, 67.5 mg/day week 1, 135 mg/day weeks 2-12, 67.5 mg/day weeks 13-24
- Population
- Adults aged 60 or older with mild cognitive impairment due to Alzheimer's disease; analysis of the original randomised groups (zinc vs placebo) at 24 weeks
Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial.2025PMID:41008575Permalink